Stay updated with breaking news from Universal Registration Document. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate's second generation ANKET, for the treatment
FY24 RESULTS Paris | May 23rd, 2024 DISCLAIMER ...
Answers to the written questions 2024 of the Forum pour l'Investissement Responsable This document is a free translation for convenience...
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took
OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases Nantes,...